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Spectrum of Intracranial Parenchymal Lesions in Patients with 
Human Immunodeficiency Virus Infection in the Republic of 
Korea
The incidence of specific intracranial parenchymal lesions of HIV-infected patients varies 
considerably between countries. In the Republic of Korea, the number of HIV-infected 
patients is increasing, but little is known regarding the spectrum of intracranial 
parenchymal lesions in these patients. The aim of the present study was to obtain this 
information. To identify HIV patients with intracranial parenchymal lesions, the electronic 
database of radiological reports for 1,167 HIV-infected patients, seen from 1999 to 2008 at 
the Seoul National University Hospital, were reviewed. Neuroradiologic studies were 
performed on 165 of these patients, and intracranial parenchymal lesions were detected in 
40 (3.4%) of them. Thirty-seven were male, and median age was 41 yr (range, 26-61). At 
the time of the diagnosis of intracranial parenchymal lesions, median CD4
+ lymphocyte 
count was 40 cells/μL (range 5-560) and in 33 (82.5%) patients, it was less than 200 cells/
μL. Progressive multifocal leukoencephalopathy (12 patients) is the most frequent 
intracranial parenchymal lesions, followed by intracranial tuberculoma (7 patients), primary 
central nervous system lymphoma (7 patients), intracranial cryptococcoma (4 patients), 
Toxoplasma encephalitis (4 patients), and disseminated non-tuberculous mycobacterial 
infection (3 patients). 
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INTRODUCTION
Neurologic manifestations are frequent in patients with human 
immunodeficiency virus (HIV) infection. They constitute the 
initial presentation in 10% of patients, and 30% to 50% develop 
neurologic complications during the course of the disease (1). 
Autopsy shows involvement of the nervous system in up to 80% 
of cases (2). Patients with HIV infection presenting with changed 
mental status or abnormal neurologic examination are frequent-
ly found to have intracranial parenchymal lesions (3). Various 
HIV related opportunistic infections and malignancies can cause 
these lesions (4). The relative frequencies of specific intracranial 
parenchymal lesions are very variable between countries, since 
the mode of infection and prevalence of infection with particu-
lar microorganisms such as Toxoplasma gondii and Epstein Barr 
virus (EBV) differ (5). 
Since the first case of acquired immunodeficiency syndrome 
(AIDS) in Korea reported in 1985, the number of HIV-infected 
patients has increased every year (6). As of December 2008, the 
cumulative number of documented patients with HIV infection 
in Korea was 6,120 (7). However, although Kim et al. (8) report-
ed neurologic complications of 34 Korean patients with HIV in-
fection, knowledge of the spectrum of intracranial parenchymal 
lesions is limited to a few case reports (9-11). Hence, we have 
investigated the spectrum of intracranial parenchymal lesions 
in HIV-infected patients in the Republic of Korea.
 
MATERIALS AND METHODS
Patients
We reviewed the medical records of 1,167 HIV-infected patients 
who were at least 16 yr old and visited the Seoul National Uni-
versity Hospital Infectious Disease Clinic more than once be-
tween January 1999 and December 2008. The patients with in-
tracranial parenchymal lesions were identified from the elec-
tronic database of radiological reports. The study protocol was 
approved by the Institutional Review Board of Seoul National 
University Hospital (IRB No. H-0910-018-296).
Definitions
Diagnoses of intracranial parenchymal lesions were classified 
as definite, presumptive, or probable. A definite diagnosis was 
defined as a diagnosis based on histological proof of a cerebral 
disorder from a brain tissue specimen obtained by stereotactic Choe PG, et al.  •  Intracranial Parenchymal Lesions in HIV-infected Patients in Korea
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brain biopsy. Presumptive diagnostic criteria for intracranial 
parenchymal lesions were as follows: 1) presumptive progres-
sive multifocal leukoencephalopathy (PML), defined as posi-
tive JC virus DNA on polymerase chain reaction (PCR) from a 
cerebrospinal fluid (CSF) specimen, accompanied by a typical 
magnetic resonance imaging (MRI) pattern (12); 2) presump-
tive intracranial tuberculoma or disseminated non-tuberculous 
mycobacteria (NTM) disease, defined as evidence of lesions with 
mass effect from brain imaging and microbiological confirma-
tion of tuberculosis or NTM from CSF or extra-cerebral speci-
mens (13); 3) presumptive Toxoplasma encephalitis, defined as 
recent onset of focal neurologic abnormalities consistent with 
intracranial disease or a reduced level of consciousness, evidence 
of a lesion with mass effect or contrast enhancement by brain 
imaging, and positive serum antibody to T. gondii (14); 4) pre-
sumptive intracranial cryptococcoma, defined as evidence of 
lesions with mass effect from brain imaging and microbiologi-
cal confirmation of Cryptococcus neoformans from CSF speci-
mens (15); 5) presumptive cytomegalovirus encephalitis, de-
fined as compatible neuroradiologic findings and positive cyto-
megalovirus DNA on PCR from CSF specimen (16). Probable 
diagnoses were determined by a board-certified infection dis-
ease specialist based on clinical and neuroradiological findings; 
the criteria were as follows (17): 1) probable PML, defined as 
presence of steady progression of focal neurologic deficit with a 
typical MRI pattern, namely asymmetric, non-enhancing, T2-
hyperintense white matter abnormalities without mass effect; 2) 
probable HIV encephalopathy, defined as presence of progres-
sive cognitive impairment with diffuse, bilateral, non-enhanc-
ing white-matter hyperintense lesions on MRI, and exclusion of 
opportunistic central nervous system (CNS) infections by exam-
ination of CSF; 3) probable primary CNS lymphoma, defined as 
evidence of a lesion with mass effect from brain imaging, exclu-
sion of opportunistic CNS infections by examination of CSF, and 
response to radiation and/or chemotherapy. 
Statistical analysis
Continuous variables are expressed as median and interquar-
tile range (IQR) values. Difference in the incidence of intracra-
nial parenchymal lesions by calendar years were analyzed us-
ing the Poisson regression. Statistical analyses were performed 
with SPSS software (version 17.0).
 
RESULTS
Study population
We treated 1,167 HIV-infected patients between 1999 and 2008. 
Total follow-up duration was 4,304 person-years and median 
follow-up duration per person was 3.16 yr (IQR, 0.93-6.03). 
  One thousand and sixty seven (91.4%) of the patients were 
male, 442 (41.4%) of whom had the risk factor of homosexual 
behavior. All patients were Korean and the median age was 37 
yr (IQR, 30-45). The median CD4
+ lymphocyte count at first visit 
to the study hospital was 230 cells/μL (IQR, 96-360), and the 
median CD4
+ lymphocyte count at nadir during follow-up was 
200 cells/μL (IQR, 80-300). Of 938 patients tested for antibody 
against T. gondii, 41 (4.3%) were positive (Table 1). 
Incidence of intracranial parenchymal lesion
We performed neuroradiologic studies on the 165 patients with 
neurological manifestation reported among the 1,167 eligible 
patients, and found intracranial parenchymal lesions in 40 (3.4 
%) of them. Thirty three (82.5%) of the intracranial parenychy-
mal lesions were multiple lesion, and 23 (57.5%) were enhanced 
on contrast-enhanced MRI. The overall incidence of intracrani-
al parenchymal lesions was 0.93 per 100 person-years, and the 
incidence of intracranial parenchymal lesions (per 100 person-
years) declined from 2.21 in 1999 to 0.69 in 2008 (P=0.003). 
  Of the 40 patients with intracranial parenchymal lesions, 37 
(92.5%) were male, and the median age was 41 yr (IQR, 35-48). 
For 19 (47.5%) of these patients, the intracranial parenchymal 
lesion was the initial presentation of HIV infection. The median 
CD4
+ lymphocyte count at nadir during follow-up was 28 cells/
Table 1. Baseline characteristics of 1,167 study patients and HIV-infected patients 
with intracranial parenchymal lesions seen at Seoul National University Hospital, 
January 1999 to December 2008
Characteristics
Enrolled patients 
(n=1,167)
Patients with 
intracranial 
parenchymal lesions 
(n=40)
Male, n (%) 1,067 (91.4%)  37 (92.5%)
Age, median years (IQR)     37 (30-45) 41 (35-48)
HIV transmission route, n (%)
   MSM 
   Heterosexual
   Blood product
   Unknown
   442 (37.9%)
   409 (35.0%)
   19 (1.6%)
   297 (25.5%)
 15 (37.5%)
 19 (47.5%)
0
   6 (15.0%)
Seropositivity for T. gondii, n (%)   41* (4.3%)    4 (10.0%)
Follow-up duration, n (%)
   -12 months
   13-36 months
   37-60 months
   61 months-
   305 (26.1%)
   259 (22.2%)
   223 (19.1%)
   380 (32.6%)
 11 (27.5%)
   9 (22.5%)
   6 (15.0%)
 14 (30.0%)
CD4
+ lymphocyte count at entry to 
  the present study (cells/μL), n (%)
†
   -50
   51-200
   201-350
   351-
   195 (16.8%)
   317 (27.3%)
   351 (30.2%)
   299 (25.7%)
 23 (57.5%)
   9 (22.5%)
   4 (10.0%)
   4 (10.0%)
CD4
+ lymphocyte count at nadir during 
  the present study (cells/μL), n (%)
†
   -50
   51-200
   201-350
   351-
   226 (19.4%)
   364 (31.3%)
   390 (33.6%)
   182 (15.7%)
 25 (62.5%)
 10 (25.0%)
   4 (10.0%)
 1 (2.5%)
*Of these patients, 938 (80.4%) were tested for antibody against T. gondii; 
†CD4
+ 
lymphocyte count was not available in 5 (0.4%) patients.
MSM, Men who have sex with men.Choe PG, et al.  •  Intracranial Parenchymal Lesions in HIV-infected Patients in Korea
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vation period, two (16.7%) were lost to follow-up, and nine (75.0 
%) were improved with antiretroviral therapy. Of the 7 patients 
with intracranial tuberculoma, one (14.3%) died during the ob-
servation period, and six (85.7%) were improved with anti-my-
cobacterial treatment. Of the 7 patients with primary CNS lym-
phoma, two (28.6%) died during the observation period, one 
(14.3%) was lost to follow-up, and four (57.1%) were improved 
with systemic chemotherapy and/or cranial radiation therapy. 
The clinical features of the patients are summarized in Table 3.
 
DISCUSSION
In the present study, PML, intracranial tuberculoma, and pri-
mary CNS lymphoma were the most frequent intracranial pa-
renchymal lesions. This situation contrasts with the outcome in 
other countries where Toxoplasma encephalitis is reported to 
be the most frequent intracranial parenchymal lesions (2-5).
  Toxoplasma encephalitis is the most common intracranial 
parenchymal lesion in patients with AIDS in most Western and 
African countries. In the United States, where the prevalence of 
seropositivity for T. gondii in adult population is around 30%, 
Toxoplasma encephalitis develops in 3% to 10% of patients with 
AIDS (18). In contrast, the seroprevalence of T. gondii ranges 
from 1% to 10% in the Korean population (19, 20), and it was 4% 
in the present study. This might be the reason for low prevalence 
of Toxoplasma encephalitis in Korea (21). Our results may also 
have been affected by the introduction of prophylaxis and high-
ly active antiretroviral therapy (HAART). In the United State, the 
incidence of Toxoplasma encephalitis decreased initially due to 
widespread prophylaxis for pneumocystis pneumonia using tri-
methoprim-sulfamethoxazole, which also prevents toxoplas-
mosis (22). Since the era of HAART, there has been a further de-
cline in the incidence of Toxoplasma encephalitis (23). As the 
HAART has been available in Korea since 1999, it may have start-
ed to influence the incidence of Toxoplasma encephalitis.
  PML is caused by the polyomavirus JCV. This double-strand-
ed DNA virus infects 90% of the normal adult population world-
wide and remains quiescent in the kidney without causing any 
Table 2. Prevalence of intracranial parenchymal lesions in 1,167 HIV-infected patients seen at Seoul National University Hospital, January 1999 to December 2008
Overall Classification of diagnoses
No. (%) Definite Presumptive Probable
Progressive multifocal leukoencephalopathy 12 (1.0)   4   3 5
Intracranial tuberculoma   7 (0.6)   7
Primary CNS lymphoma   7 (0.6)   5 2
Toxoplasma encephalitis   4 (0.3)   2   2
Cerebral cryptococcoma   4 (0.3)   4
Disseminated NTM diseases   3 (0.3)   1   2
HIV encephalopathy   2 (0.2) 2
Cytomegalovirus encephalitis   1 (0.1)   1
Overall intracranial parenchymal lesions 40 (3.4) 12 19 9
CNS, central nervous system; NTM, non-tuberculous mycobacteria.
μL (IQR, 10-95). At the time of the diagnosis of the intracranial 
parenchymal lesions, median CD4
+ lymphocyte count was 40 
cells/μL (IQR, 13-150) and in 33 (82.5%) of the patients, the CD4
+ 
lymphocyte count was less than 200 cells/μL (Fig. 1).
Diagnoses of intracranial parenchymal lesion
A definite diagnosis was obtained in 12 (30%) of the 40 patients 
with intracranial parenchymal lesions, a presumptive diagnosis 
was obtained in 19 (47.5%), and a probable diagnosis was obta–
ined in nine (22.5%). All of the diagnoses were included among 
AIDS-defining diseases. PML was diagnosed in twelve cases (30.0 
%), intracranial tuberculoma in seven (17.5%), primary CNS lym-
phoma in seven (17.5%), cerebral cryptococcoma in four (10.0%), 
Toxoplasma encephalitis in four (10.0%), disseminated NTM 
disease in three (7.5%), HIV encephalopathy in two (5.0%) pa-
tients, and CMV encephalitis in one (Table 2). 
Outcome of intracranial parenchymal lesions
Of the 12 patients with PML, one (8.3%) died during the obser-
Fig. 1. CD4
+ lymphocyte counts at the time of diagnosis of each intracranial paren- 
chymal lesion in HIV-infected patients. Bars denote median values.
PML, Progressive multifocal leukoencephalopathy; PCNSL, Primary central nervous 
system lymphoma; TOXO, Toxoplasma encephalitis; NTM, Disseminated non-tuber- 
culous mycobacteria disease; CMV, Cytomegalovirus encephalitis.
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disease. In conditions of immunosuppression, JCV is activated 
and undergoes lytic infection in oligodendrocytes, causing PML 
(24). Before the AIDS era, PML was a rare disease affecting main-
ly patients with chronic lymphocytic leukemia, non-Hodgkin’s 
lymphoma, or organ transplant recipients. At the beginning of 
the AIDS epidemic, up to 5% of HIV-infected patients developed 
PML (25). Unlike the other opportunistic infections, the inci-
dence of PML has not decreased since the availability of HAART 
and has even shown a slight increase; hence the importance of 
PML as a cause of intracranial parenchymal lesions is increas-
Table 3. Clinical features and diagnoses in the HIV-infected patients with intracranial parenchymal lesions, seen at Seoul National University Hospital from 1999 to 2008
Sex/Age 
(yr)
Neurologic symptoms
CD4*
(cells/μL)
HIV RNA*
(copies/mL)
Brain MRI findings Diagnosis Clue Outcome  
M/49
Motor aphasia, memory 
disturbance
150 126,000 Ill-defined T2 high SI lesions [Definite] PML Biopsy proven Improved
M/43 Altered mentality 10   57,019 Diffuse T2 high SI lesions [Definite] PML Biopsy proven Expired
M/40 Hemiplegia, dysarthria 307 258,000 Multiple T2 high SI nodules [Definite] PML Biopsy proven Improved
M/46 Memory disturbance 10 121,298 Diffuse T2 high SI lesions [Definite] PML Biopsy proven Improved
M/36 Memory disturbance 18   44,700 Diffuse T2 high SI lesions [Presumptive] PML CSF JC PCR+ F/U loss
M/61 Dysorientation 160   78,000 Multifocal T2 high SI lesions [Presumptive] PML CSF JC PCR+ F/U loss
M/36 Hemianopsia, diplopia 6   12,900 Multifocal T2 high SI lesions [Presumptive] PML CSF JC PCR+ Improved
M/41 Memory disturbance 60 125 Multiple T2 high SI lesions [Probable] PML (IRIS) Clinical feature Improved
M/34 Dysarthria 190 <40 Multifocal T2 high SI lesions [Probable] PML Clinical feature Improved
M/59 Dizziness 260 40200 Multifocal T2 high SI lesions [Probable] PML Clinical feature Improved
M/46
Dysarthria, gait 
disturbance
80   79,300 Multiple T2 high SI lesions [Probable] PML Clinical feature Improved
M/35 Dysarthria, ataxia 20 750,000 T2 high SI lesions [Probable] PML Clinical feature Improved
M/27 Headache 80 149,324 Multiple rim enhancing nodules [Presumptive] Tuberculoma Sputum culture+ Improved
M/48 Hemiplegia 40   59,540 Small peripheral enhanced lesion [Presumptive] Tuberculoma Ascites culture+ Improved
M/26 Headache 230 750,000 Multiple patchy high SI lesions [Presumptive] Tuberculoma Sputum culture+ Improved
F/41 Seizure 40 Multiple enhancing nodules [Presumptive] Tuberculoma CSF culture+ Expired
M/54 Altered mentality 10 188,000 Small nodular lesions [Presumptive] Tuberculoma CSF culture+ Improved
M/43 Altered mentality 19 791,000 Small enhancing nodular lesions [Presumptive] Tuberculoma Sputum culture+ Improved
M/27 Headache 334 <40 Small rim enhancing nodules [Presumptive] Tuberculoma (IRIS) CSF culture+ Improved
M/50 Weakness 34 <40 Large (4 cm) enhancing lesion
[Definite] Primary CNS Lymphoma, 
DLBL 
Biopsy proven Improved
M/45 Hemiplegia 5   22,111 Rim enhancing mass [Definite] Primary CNS Lymphoma Biopsy proven Expired
F/48 Altered mentality 10 <40 Multiple rim enhancing lesions [Definite] Primary CNS Lymphoma Biopsy proven Expired
M/38 Seizure 40   17,000
Multiple conglomerated rim  
enhancing lesions
[Definite] Primary CNS Lymphoma Biopsy proven Improved
M/39 Headache 204 109,000 Enhancing mass-like lesion
[Definite] Primary CNS Lymphoma, 
Burkitt’s
Biopsy proven  Improved
M/36 Memory disturbance 12     NC Rim enhancing mass [Probable] Primary CNS lymphoma Clinical feature F/U loss
M/33 Behavior abnormality 334 474,000 Multiple rim enhancing nodules [Probable] Primary CNS lymphoma Clinical feature Improved
M/56 Headache, Fever, N/V 60 <400 Non enhancing nodular lesions [Presumptive] Cryptococcoma CSF culture+ Improved
M/44 Headache, N/V 14 750,000 Multifocal patchy lesions [Presumptive] Cryptococcoma CSF culture+ Improved
M/35 Headache, N/V 70 <331 Enhancing nodular lesions [Presumptive] Cryptococcoma (IRIS) CSF culture+ Improved
M/40 Headache 60 25,938 Multiple nodular lesions [Presumptive] Cryptococcoma (IRIS) CSF culture+ Improved
M/31 Seizure 150 <40 Multiple tiny high SI lesions [Definite] Disseminated NTM disease Biopsy proven Improved
M/41 Altered mentality 2 750,000 Multiple rim enhancing lesions
[Presumptive] Disseminated NTM 
disease
Sputum culture+
Hopeless 
discharged
M/35 Headache 9 553,000 Multiple rim enhancing nodules
[Presumptive] Disseminated NTM 
disease
Sputum culture+
Hopeless 
discharged
M/58 Hemiplegia 5 104,000 Rim enhancing mass [Definite] Toxoplasma encephalitis Biopsy proven Improved
M/43 Hemiplegia 27 361,000 Large rim enhancing lesion [Definite] Toxoplasma encephalitis Biopsy proven  Expired
F/53 Altered mentality 40 214,516 Multiple rim enhancing lesions [Presumptive] Toxoplasma encephalitis Toxo IgG+ Expired
M/38 Cognitive dysfunction 19 309,000 Rim enhancing cavitary lesion  [Presumptive] Toxoplasma encephalitis Toxo IgG+ Improved
M/27 Headache 370   99,098 Small T2 high SI lesions [Probable] HIV encephalopathy Clinical feature Improved
M/51 Headache 30 750,000 Diffuse high SI lesions [Probable] HIV encephalopathy Clinical feature Improved
M/34 Headache 60 <25
Patchy T2 hyper-intense  
enhancing lesion
[Presumptive] CMV encephalitis CSF CMV PCR+ Improved
*CD4
+ lymphocyte count and HIV RNA at the time of diagnosis of intracranial parenchymal lesions.
HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; SI, signal intensity; PML, progressive multifocal leukoencephalopathy; IRIS, immune reconstitutional 
inflammatory syndrome; DLBL, diffuse large B cell lymphoma; CSF, cerebrospinal fluid; PCR, polymerase chain reaction; CNS, central nervous system; N/V, nausea/vomiting; F/
U, follow-up; NTM, non-tuberculous mycobacteria; Toxo, Toxoplasma gondii.Choe PG, et al.  •  Intracranial Parenchymal Lesions in HIV-infected Patients in Korea
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ing (23). The introduction of HAART did not decrease the inci-
dence of PML, but it improved the prognosis of PML. Before 
HAART era, the median interval from the time of symptom pre-
sentation to death was 2 to 4 months (25). In the HAART era, 
median survival has increased to 10.5 months, and half the pa-
tients survive for more 1 yr (26). In the present study, 9 (75.0%) 
of the 12 patients with PML improved with antiretroviral thera-
py, two were lost to follow-up, and only one died.
  Intracranial tuberculoma is one of the most important causes 
of intracranial parenchymal lesions among AIDS patients, and 
is found in 10% of patients co-infected with HIV and tuberculo-
sis (27). Because tuberculosis is the most frequent HIV-related 
opportunistic infection in HIV-infected patients in Korea (28, 29), 
we expected that intracranial tuberculomas would also be com-
mon in our population. During the study period, 73 patients with 
HIV infection were admitted for tuberculosis. Seven (9.6%) of 
them had intracranial tuberculomas. 
  Primary CNS lymphoma, which affected 2% of patients with 
AIDS at the beginning of the epidemic, has seen its incidence 
decrease considerably in the HAART era (30). In the present 
study, it developed in five patients; none of whom received an-
tiretroviral therapy at the time of diagnosis. Detection of EBV 
DNA by PCR in the CSF is reported to have a sensitivity of 80% 
to 90% and a specificity of 87% to 98% for the diagnosis of pri-
mary CNS lymphoma (31), but we did not test any patients for 
EBV DNA of CSF in the present study. 
  Cryptococcus neoformans infection in patients infected with 
HIV usually causes subacute meningitis, but on rare occasion, 
it causes intracranial parenchymal lesions such as cryptococ-
coma (15). In some patients with cryptococcal meningitis, the 
use of HAART can cause immune reconstitution inflammatory 
syndrome (IRIS) (32). IRIS associated with cryptococcal infec-
tion usually presents as culture-negative meningitis, but some-
times as cryptococcoma (32). In the present study, 10 patients 
were admitted for cryptococcal meningitis; two had intracranial 
parenchymal lesions when initially diagnosed with cryptococcal 
meningitis, and two had intracranial cryptococcoma with IRIS. 
  There are some limitations to the present study. First, the in-
cidence of intracranial parenchymal lesions might be underes-
timated, because some patients with intracranial parenchymal 
lesions may not have been evaluated despite the presence of 
neurologic problems. Second, since definite and presumptive 
diagnoses were achieved in only 77% of the patients, the pres-
ent study results may not reflect the true spectrum of intracra-
nial parenchymal lesions entirely accurately. However, the data 
obtained are significant as representing the first description of 
the spectrum of intracranial parenchymal lesions in HIV-infect-
ed patients in Korea.
  In the present study, we investigated 1,167 HIV patients, mak-
ing up 19.1% of all Korean patients with HIV infection as of De-
cember 2008, and there were no significant differences between 
the demographic findings including age, sex, and transmission 
route for the present study population and the national statistics 
for all Korean patients with HIV infection (7). Among the intra-
cranial parenchymal lesions developed in Korean patients with 
HIV infection in the HAART era, PML is the most frequent cause, 
followed by intracranial tuberculoma, primary CNS lymphoma, 
intracranial cryptococcoma, and Toxoplasma encephalitis.
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